The Signal
$IOVA operationalizes the only durable biotech-AI thesis worth owning: precision oncology through manufacturing footprint + biomarker stratification, not discovery acceleration alone. Q3 beat ($122M rev, 60% margin, $382M runway into 2029) validates profitability glide; sBLA filing for NSCLC KRAS WT cohort (85.7% frontline ORR, newly added cohort 5 with 22 KRAS WT/HER2 WT smokers showing 59.1% ORR) removes clinical binary and de-risks second regulatory pathway. 150+ ATCs operationalized = manufacturing moat vs. CAR-T heterogeneity. Precision TIL (biomarker-driven dosing) + IOV-5001 IL-12 engineered TIL (trial started Sept 2026) unlock 7x melanoma TAM expansion into soft tissue sarcomas (55% ORR).
What's Moving
- $IOVA (precision TIL profitability + sBLA binary removal) — sBLA filing on narrow KRAS WT label de-risks accelerated approval pathway; $382M runway into 2029 means zero cash risk into 2H27. Cohort 5 addition (59.1% ORR in KRAS WT/HER2 WT smokers vs. 15–18% standard-of-care) telegraphs FDA confidence on narrower label. (via @biotechscanner)
- IOV-5001 IL-12 tethered TIL (interim data incoming) — Trial started Sept 2026; single-patient CR after TIL failure at NCI signals reduced toxicity reformulation. First dataset could reshape soft tissue sarcoma addressable market and unlock $20–25M revenue floor by 2H27. Biomarker-driven dosing operationalizes payer moat.
- Precision TIL biomarker stratification operationalizes at scale — Dr. Brian Gastman (EVP, Translational Medicine) publicly signaled "things to share soon"; cohort 5 addition confirms genetic biomarker-driven dosing is live. Separates Amtagvi from commodity checkpoint inhibitor comparisons; locks reimbursement ceiling upside.
Crosscurrents
- $IOVA valuation vs. payer adoption velocity — $IOVA repeating $20+ price targets (HC Wainwright latest); assumes 2027 approval velocity + ex-US self-pay adoption ramp. If PDUFA slips on sBLA or payer coverage tightens (like $IBRX Anktiva Q3 $49M vs. Q2 $51M sequential decline despite "BCG-naive claims"), narrow label approval may cap near-term revenue trajectory at $200–300M by 2028, not $3B management infers.
- Manufacturing capacity scaling risk — Current 5K ATCs with modular design to 10K; ramp-up execution in 2027 will determine whether manufacturing moat holds or becomes bottleneck.
Tradecraft
Desk Notes
- @biotechscanner — $IOVA is the only biotech he'd rather own; management is "awesome"; billionaire chair/CEO (Duggan connection) never sold at $18 or $17; expects share price to $50 at 5K ATC capacity = ~$3B revenue floor.
- @biotech2k1 — Skeptical of AI-cure narratives; biology is "messy and complex"; finds most AI biotech hype unsupported by clinical translation reality.